Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey

Immune checkpoint inhibitors (ICI) block negative regulatory molecules, such as CTLA-4, PD-1 and PD-L1, in order to mount an antitumor response. T cells are important for antiviral defense, but it is not known whether patients with cancer treated with ICI are more or less vulnerable to viral infecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghosh, Nilasha, Tirpack, Aidan, Chan, Karmela K, Bass, Anne R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569707/
https://www.ncbi.nlm.nih.gov/pubmed/33067320
http://dx.doi.org/10.1136/jitc-2020-001550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569707/
https://www.ncbi.nlm.nih.gov/pubmed/33067320
http://dx.doi.org/10.1136/jitc-2020-001550

Ejemplares similares